Link to story on FDA News and Events Page
The U.S. Food and Drug Administration has approved direct to consumer marketing of 23andMe Personal Genome Service Genetic Health Risk tests for 10 diseases including Parkinson's disease and late onset Alzheimer's disease. It is important to recognize that genetic tests alone cannot determine a person’s overall risk of developing a neurodegenerative disease; this is because there are other factors that contribute to the development of a disease including environmental and occupational exposures to toxic chemicals.
Link to story on FDA News and Events Page
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
AuthorDr. Marcia Ratner shares and reviews the news. Archives
February 2023
Categories |